|
|
 |
|
Viewing report
|
|
|
|
Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, April 2011, Pages: 84
Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global bone metastases therapeutics market. The report identifies the key trends shaping and driving the global bone metastases therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global bone metastases therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global bone metastases therapeutics market was valued at $1,425m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 12% over the next seven years to reach $6,390m by 2017. Although the drug pipeline for the treatment of bone metastases is strong, the launch of Amgen’s Xgeva in early 2010, which is another breakthrough for bone metastases patients, is the primary driver for increased market growth. The market remains well-served with the current marketed products, most of which are significantly efficacious in their respective target areas. Essentially, the global bone metastases market is heading towards a phase of continuous growth, leveraging the current opportunities.
Scope
The report provides information on the key drivers and challenges of the bone metastases market. Its scope includes -
- Annualized global bone metastases market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as as cathepsin K inhibitors, TGF (transforming growth factor) inhibitors, lysophosphatidic acid (LPA), G-protein-coupled receptors (GPCRs) inhibitors, integrin receptor antagonist, ATPase-dependent hydrogen ion inhibitor, Alpha-radiopharmaceutical, and a weekly oral zoledronic acid.
- Analysis of the current and future competition in the global bone metastases market. Key market players covered are Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Bayer-Algeta, Merrion Pharmaceuticals Plc., Ablynx, Genta Incorporated, Galapagos NV, Catena Pharmaceuticals, Inc, Digna Biotech, S.L., Medivir AB, and Amura Holdings.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the bone metastases therapeutics market.
- Analysis of key recent licensing and partnership agreements in bone metastases therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global bone metastases therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global bone metastases therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global bone metastases therapeutics market landscape? – Identify, understand and capitalize.
|
|
|
|
